Some experts have called for the lowest grade of prostate cancer–biopsy Gleason Grade Group (GGG) 1–to be reclassified as “benign.” A new study has not only confirmed previous research regarding the rate of misdiagnosis among patients with a biopsy GGG1, but identifies which patients should receive genomic and follow-up PSA testing to confirm their “benign” diagnosis.